Dear peats!
As you all know, serotonin has a direct aggregative coagulant effect through the 5-ht2 family of receptors. And so, aspirin has the strongest antiplatelet effect at doses below 325 mg. We also know that aspirin has the most potent beneficial effect on tyrosine hydroxylase at a concentration of 2μM.
Does this mean that the antiserotonin effect of aspirin will not extend to its uncoupling effect, since this effect is achieved at a concentration of 0.5mM, which, for a moment, is 250 times greater, and will only occur at the most strongly blood-thinning doses?
Anyone there? @haidut , @Lokzo , @Hans , @charlie
As you all know, serotonin has a direct aggregative coagulant effect through the 5-ht2 family of receptors. And so, aspirin has the strongest antiplatelet effect at doses below 325 mg. We also know that aspirin has the most potent beneficial effect on tyrosine hydroxylase at a concentration of 2μM.
Does this mean that the antiserotonin effect of aspirin will not extend to its uncoupling effect, since this effect is achieved at a concentration of 0.5mM, which, for a moment, is 250 times greater, and will only occur at the most strongly blood-thinning doses?
Anyone there? @haidut , @Lokzo , @Hans , @charlie
